- Home
- SNTI
as 11-25-2025 10:00am EST
Senti Biosciences Inc is a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 53.6M | IPO Year: | N/A |
| Target Price: | $8.75 | AVG Volume (30 days): | 97.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.98 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.26 - $16.94 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.00% |
Latest Senti Biosciences Inc. News
SNTI Breaking Stock News: Dive into SNTI Ticker-Specific Updates for Smart Investing
GlobeNewswire
12 days ago
Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December
GlobeNewswire
22 days ago
Senti Bio to Present Updated Clinical Results of First-in-Class Logic Gated CD33/FLT3 Cell Therapy, SENTI-202, at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire
a month ago
Senti Bio to Present at Chardan's 9th Annual Genetic Medicines Conference
MT Newswires
a month ago
HC Wainwright Initiates Coverage on Senti Biosciences With Buy Rating, $12 Price Target
GlobeNewswire
2 months ago
Senti Bio to Present at BioJapan
GlobeNewswire
5 months ago
Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference
MT Newswires
5 months ago
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
GlobeNewswire
5 months ago
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Compare SNTI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SNTI Senti Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.